Abstract:ABSTRACT Fecal microbiota transplantation (FMT) is an innovative and promising treatment for inflammatory bowel disease (IBD), which is related to the capability of FMT to supply functional microorganisms to improve recipient gut health. Numerous studies have highlighted considerable variability in the efficacy of FMT interventions for IBD. Several factors, including the composition of the donor microorganisms, significantly affect the efficacy of FMT in the treatment of IBD. Consequently, identifying the functional microorganisms in the donor is crucial for enhancing the efficacy of FMT. To explore potential common anti-inflammatory bacteria with therapeutic implications for IBD, germ-free (GF) BALB/c mice were pre-colonized with fecal microbiota obtained from diverse donors, including Macaca fascicularis (MCC_FMT), Bama miniature pigs (BP_FMT), beagle dogs (BD_FMT), and C57BL/6 J mice (Mice_FMT). Subsequently, mice were treated with dextran sodium sulfate (DSS). As expected, the symptoms of colitis were alleviated by MCC_FMT, BP_FMT, BD_FMT, and Mice_FMT, as demonstrated by the prevention of an elevated disease activity index in mice. Additionally, the utilization of distinct donors protected the intestinal barrier and contributed to the regulation of cytokine homeostasis. Metagenomic sequencing data showed that the microbial community structure and dominant species were significantly different among the four groups, which may be linked to variations in the anti-inflammatory efficacy observed in the respective groups. Notably, Lactobacillus reuteri and Flavonifractor plautii were consistently present in all four groups. L. reuteri exhibited a significant negative correlation with IL-1β, and animal studies further confirmed its efficacy in alleviating IBD, suggesting the presence of common functional bacteria across different donors that exert anti-inflammatory effects. This study provides essential foundational data for the potential clinical applications of FMT. IMPORTANCE Despite variations in efficacy observed among donors, numerous studies have underscored the potential of fecal microbiota transplantation (FMT) for managing inflammatory bowel disease (IBD), indicating the presence of shared anti-IBD bacterial species. In the present study, the collective anti-inflammatory efficacy observed across all four donor groups prompted the identification of two common bacterial species using metagenomics. A significant negative correlation between Lactobacillus reuteri and IL-1β was revealed. Furthermore, mice gavaged with L. reuteri successfully managed the colitis challenge induced by dextran sodium sulfate (DSS), suggesting that L. reuteri may act as an efficacious bacterium mediating shared anti-inflammatory effects among variable donors. This finding highlights the utilization of variable donors to screen FMT core bacteria, which may be a novel strategy for developing FMT applications.

Fecal microbiota transplantation modulates the intestinal microbiome and alleviates Escherichia coli infected outcomes in mice

Akkermansia and the microbial metabolites butyric acid and deoxycholic acid play key roles in fecal microbiota transplantation for the treatment of campylobacteriosis in mice

Fecal microbiota transplantation attenuates Escherichia coli infected outgrowth by modulating the intestinal microbiome

Fecal Microbiota Transplantation (FMT) Alleviates Experimental Colitis in Mice by Gut Microbiota Regulation

Fecal Microbiota Transplantation Beneficially Regulates Intestinal Mucosal Autophagy and Alleviates Gut Barrier Injury

Fecal microbiota transplantation ameliorates experimental colitis via gut microbiota and T-cell modulation

The Evaluation of Fecal Microbiota Transplantation Vs Vancomycin in a Clostridioides Difficile Infection Model.

Treatment and mechanism of fecal microbiota transplantation in mice with experimentally induced ulcerative colitis

Beneficial Effects of Fecal Microbiota Transplantation on Ulcerative Colitis in Mice

Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii served as key components of fecal microbiota transplantation to alleviate colitis

Fecal microbiota transplantation reduces mouse mortality from Listeria monocytogenes infection

Akkermansia muciniphila identified as key strain to alleviate gut barrier injury through Wnt signaling pathway

Colonization of microbiota derived from Macaca fascicularis, Bama miniature pigs, beagle dogs, and C57BL/6J mice alleviates DSS-induced colitis in germ-free mice

Colonization of microbiota derived from Macaca fasciculari s, Bama miniature pigs, beagle dogs, and C57BL/6J mice alleviates DSS-induced colitis in germ-free mice

Human Fecal Microbiota Transplantation Reduces the Susceptibility to Dextran Sulfate Sodium-Induced Germ-Free Mouse Colitis

P830 Adherent-invasive Escherichia coli in inflammatory bowel disease impacts faecal microbiota transplantation efficacy by hindering engraftment of beneficial bacteria

Fecal microbiota transplantation inhibits colorectal cancer progression: Reversing intestinal microbial dysbiosis to enhance anti-cancer immune responses

Shifts and importance of viable bacteria in treatment of DSS-induced ulcerative colitis mice with FMT

Fecal microbiota transplantation: effectiveness, complexities, and lingering concerns

Lower fecal microbiota transplantation ameliorates ulcerative colitis by eliminating oral-derived Fusobacterium nucleatum and virulence factor

Lactiplantibacillus Plantarum and Faecal Microbiota Transplantation Can Improve Colitis in Mice by Affecting Gut Microbiota and Metabolomics.